Fetal Bovine Serum Market: Current Analysis and Forecast (2022-2030)

The Fetal Bovine Serum Market is expected to grow at a strong CAGR of ~8% during the forecast period. The fetal bovine serum (FBS) market is a highly competitive market that is driven by the growing demand for biopharmaceuticals and the increasing use of FBS in research and production applications. FBS is a key ingredient in the production of many biopharmaceuticals, including vaccines, monoclonal antibodies, and other therapeutic proteins. The FBS market is segmented by end-user, with the biotechnology and pharmaceutical industries being the largest segments. These industries are expected to continue to be the major drivers of the FBS market in the coming years, due to the ongoing demand for biopharmaceuticals and the increasing use of FBS in their production. The FBS market is also influenced by regulations and standards, as the production and use of FBS are regulated by government agencies. Compliance with these regulations is important for companies that sell FBS, as they must ensure that their products meet safety and quality standards. The FBS market is a dynamic and rapidly growing market that is expected to continue to be driven by the ongoing demand for biopharmaceuticals and the increasing use of FBS in research and production applications.

Based on application, the market is segmented into biopharmaceuticals, human & animal vaccines, and others. The biopharmaceuticals segment is expected to be the largest segment of the fetal bovine serum (FBS) market, driven by the increasing demand for biopharmaceuticals and the increasing use of FBS in their production. Biopharmaceuticals are complex proteins that are used to treat a wide range of medical conditions, including cancer, autoimmune diseases, and genetic disorders. The production of biopharmaceuticals typically involves the use of animal-derived products, such as FBS, as they are critical for the growth and maintenance of cells used in cell culture.

Based on end-user, the market is segmented into biotechnology & pharmaceutical industries, academic institutes, and others. The biotechnology and pharmaceutical industries are expected to continue to be the largest segments of the FBS market in the coming years, due to the ongoing demand for biopharmaceuticals and the increasing use of FBS in the production of these products. Additionally, the biotechnology and pharmaceutical industries are expected to continue to invest in research and development, which is likely to drive demand for FBS.

For a better understanding of the market adoption of the Fetal Bovine Serum industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Rest of World. North America dominated the Fetal Bovine Serum market in 2021. The North America region is expected to lead the fetal bovine serum (FBS) market, driven by the strong demand for biopharmaceuticals and the well-established biotechnology industry in the region. Additionally, the North America region has a large number of established FBS manufacturers and distributors, which is expected to support the growth of the market. Recently, in January 2022, Thermo Fisher Scientific, a leading provider of life science solutions, announced the launch of a new FBS product called Invitrogen FBS Plus. This product is intended to provide a high-quality FBS solution for research applications, and it is expected to help Thermo Fisher Scientific expand its presence in the FBS market. Another recent development in the FBS market is the increasing use of alternative products, such as recombinant FBS, in the production of biopharmaceuticals. Recombinant FBS is produced using genetically engineered cells and is intended to be a safer and more ethical alternative to traditional FBS. This trend is expected to continue to gain momentum in the coming years, which may impact the growth of the traditional FBS market.

Some of the major players operating in the market include: Thermo Fisher Scientific Inc., Sartorius AG, Danaher (Cytiva), Merck KGaA (Sigma Aldrich), HiMedia Laboratories, Bio-Techne, PAN-Biotech, Atlas Biologicals, Inc., GE Healthcare, Sera Scandia (Biowest).